FDA drug reporting sucks | Balaji Srinivasan and Lex Fridman

TL;DR

FDA's post-market surveillance system for reporting adverse drug effects is outdated and needs modernization to provide a better user experience.

Transcript

we get reviews for everything right one thing that you know like people have sort of in my view some Accord context are like oh biology thinks you should replace the FDA with the help for drugs actually there's something called phase four okay of the FDA which is so-called post-market surveillance do you know that that's actually something where in... Read More

Key Insights

• 🏣 FDA's current post-market surveillance system for reporting adverse drug effects is outdated and requires modernization.
• 👤 Modernizing the system could involve creating a user-friendly interface similar to platforms like Yelp or Amazon.
• 💁 A global database of patient and doctor reports on drugs could provide valuable information for individuals with rare or semi-rare conditions.

Questions & Answers

Q: Why is FDA's post-market surveillance system outdated?

The current system requires users to fill out a PDF form and manually upload it, which is cumbersome and outdated in the age of user-friendly interfaces and instant reporting.

Q: How can the FDA's post-market surveillance system be modernized?

One approach could involve creating a user-friendly interface where users can easily report adverse drug effects and access information on drugs. This could be similar to platforms like Yelp or Amazon.

Q: What are the benefits of modernizing the FDA's post-market surveillance system?

Modernizing the system would allow for easier reporting of adverse drug effects, facilitate access to global reports on drug effects, and provide valuable information for individuals with rare or semi-rare conditions.

Q: What are the challenges in modernizing the FDA's post-market surveillance system?

One challenge could be the regulatory and legal framework around FDA reporting. Ensuring data privacy and accuracy would also be key considerations.

Summary & Key Takeaways

• FDA's post-market surveillance system, known as phase four, allows voluntary reporting of adverse drug effects through a PDF form on their website.

• The current system is outdated and cumbersome, requiring users to fill out a PDF form and upload it manually.

• Modernizing the system could involve creating a user-friendly interface, similar to Yelp or other rating platforms, where users can easily report and access information on drugs.

• A global database of patient and doctor reports on drugs could provide valuable information for individuals with rare or semi-rare conditions.